Switch to:
Also traded in: Australia, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
AVMXY's Cash to Debt is ranked higher than
94% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. AVMXY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
AVMXY' s Cash to Debt Range Over the Past 10 Years
Min: 7  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.77
AVMXY's Equity to Asset is ranked higher than
73% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. AVMXY: 0.77 )
Ranked among companies with meaningful Equity to Asset only.
AVMXY' s Equity to Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.84 Max: 0.96
Current: 0.77
0.51
0.96
Interest Coverage No Debt
AVMXY's Interest Coverage is ranked higher than
93% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 73.78 vs. AVMXY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AVMXY' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 2
Z-Score: 3.77
WACC vs ROIC
6.07%
-1296.27%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1376.05
AVMXY's Operating margin (%) is ranked lower than
94% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. AVMXY: -1376.05 )
Ranked among companies with meaningful Operating margin (%) only.
AVMXY' s Operating margin (%) Range Over the Past 10 Years
Min: -1723.37  Med: -288.3 Max: -178.34
Current: -1376.05
-1723.37
-178.34
Net-margin (%) -873.25
AVMXY's Net-margin (%) is ranked lower than
92% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. AVMXY: -873.25 )
Ranked among companies with meaningful Net-margin (%) only.
AVMXY' s Net-margin (%) Range Over the Past 10 Years
Min: -1614.68  Med: -242.44 Max: -57.58
Current: -873.25
-1614.68
-57.58
ROE (%) -139.89
AVMXY's ROE (%) is ranked lower than
92% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.47 vs. AVMXY: -139.89 )
Ranked among companies with meaningful ROE (%) only.
AVMXY' s ROE (%) Range Over the Past 10 Years
Min: -173.32  Med: -87.94 Max: -17.34
Current: -139.89
-173.32
-17.34
ROA (%) -111.25
AVMXY's ROA (%) is ranked lower than
90% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. AVMXY: -111.25 )
Ranked among companies with meaningful ROA (%) only.
AVMXY' s ROA (%) Range Over the Past 10 Years
Min: -133.85  Med: -65.83 Max: -13.45
Current: -111.25
-133.85
-13.45
ROC (Joel Greenblatt) (%) -1057.10
AVMXY's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 3.44 vs. AVMXY: -1057.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AVMXY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4361.27  Med: -933.67 Max: -248.87
Current: -1057.1
-4361.27
-248.87
Revenue Growth (3Y)(%) -39.40
AVMXY's Revenue Growth (3Y)(%) is ranked lower than
90% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. AVMXY: -39.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AVMXY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -33.3 Max: 8.7
Current: -39.4
0
8.7
EBITDA Growth (3Y)(%) -6.60
AVMXY's EBITDA Growth (3Y)(%) is ranked lower than
67% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 4.00 vs. AVMXY: -6.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AVMXY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.1  Med: -14.35 Max: 30.8
Current: -6.6
-64.1
30.8
EPS Growth (3Y)(%) -6.60
AVMXY's EPS Growth (3Y)(%) is ranked lower than
64% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. AVMXY: -6.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AVMXY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -57.9  Med: -17.5 Max: 11.9
Current: -6.6
-57.9
11.9
» AVMXY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with AVMXY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices  
Compare:NAS:TNDM, OTCPK:QTVLF, NAS:VIVE, NAS:MSON, NAS:NVTR, NAS:SPAN, NAS:SRTS, OTCPK:TITXF, NAS:RWLK, OTCPK:ARTH, NAS:SPNE, NAS:EYES, AMEX:CVRS, OTCPK:BLOZF, NAS:DRAD, OTCPK:DIZTF, OTCPK:MRLB, NAS:EDAP, NAS:AVGR, OTCPK:BTCY » details
Traded in other countries:AVH.Australia, GCR.Germany,
Avita Medical Ltd is a medical device company. It develops and sells regenerative and respiratory medicine. It offers products such as ReCell Autologous Spray-On-Skin, Funhaler incentive asthma spacer and Breath-A-Tech spacer.

Avita Medical Ltd. manufactures & sells regenerative & respiratory medical devices. It offers tissue-engineered products for wound & skin defects, spacers for adolescent & adults, ReCell Spray-On-Skin, Funhaler for asthma & Breath-ATech, among others.

Ratios

vs
industry
vs
history
P/B 12.14
AVMXY's P/B is ranked lower than
92% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 3.08 vs. AVMXY: 12.14 )
Ranked among companies with meaningful P/B only.
AVMXY' s P/B Range Over the Past 10 Years
Min: 0.21  Med: 2.56 Max: 15
Current: 12.14
0.21
15
P/S 66.69
AVMXY's P/S is ranked lower than
95% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.02 vs. AVMXY: 66.69 )
Ranked among companies with meaningful P/S only.
AVMXY' s P/S Range Over the Past 10 Years
Min: 1.43  Med: 8.75 Max: 70
Current: 66.69
1.43
70
Current Ratio 4.31
AVMXY's Current Ratio is ranked higher than
73% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. AVMXY: 4.31 )
Ranked among companies with meaningful Current Ratio only.
AVMXY' s Current Ratio Range Over the Past 10 Years
Min: 0.3  Med: 4.9 Max: 126.2
Current: 4.31
0.3
126.2
Quick Ratio 3.52
AVMXY's Quick Ratio is ranked higher than
76% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 1.82 vs. AVMXY: 3.52 )
Ranked among companies with meaningful Quick Ratio only.
AVMXY' s Quick Ratio Range Over the Past 10 Years
Min: 0.3  Med: 4.59 Max: 126.2
Current: 3.52
0.3
126.2
Days Inventory 902.51
AVMXY's Days Inventory is ranked lower than
100% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 134.83 vs. AVMXY: 902.51 )
Ranked among companies with meaningful Days Inventory only.
AVMXY' s Days Inventory Range Over the Past 10 Years
Min: 157  Med: 358.08 Max: 902.51
Current: 902.51
157
902.51
Days Sales Outstanding 382.12
AVMXY's Days Sales Outstanding is ranked lower than
99% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. AVMXY: 382.12 )
Ranked among companies with meaningful Days Sales Outstanding only.
AVMXY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 98.69  Med: 179.48 Max: 382.12
Current: 382.12
98.69
382.12
Days Payable 1.00
AVMXY's Days Payable is ranked lower than
98% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. AVMXY: 1.00 )
Ranked among companies with meaningful Days Payable only.
AVMXY' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 328.22 Max: 1400.07
Current: 1
1
1400.07

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.40
AVMXY's 3-Year Average Share Buyback Ratio is ranked lower than
78% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. AVMXY: -17.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AVMXY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -93.8  Med: -36.9 Max: 0
Current: -17.4
-93.8
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.14
AVMXY's Price/Net Cash is ranked higher than
56% of the 98 Companies
in the Global Medical Devices industry.

( Industry Median: 16.84 vs. AVMXY: 14.14 )
Ranked among companies with meaningful Price/Net Cash only.
AVMXY' s Price/Net Cash Range Over the Past 10 Years
Min: 1.08  Med: 5.1 Max: 50.5
Current: 14.14
1.08
50.5
Price/Net Current Asset Value 14.14
AVMXY's Price/Net Current Asset Value is ranked lower than
74% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 6.51 vs. AVMXY: 14.14 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AVMXY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.07  Med: 5 Max: 339.5
Current: 14.14
1.07
339.5
Price/Tangible Book 14.14
AVMXY's Price/Tangible Book is ranked lower than
83% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 4.06 vs. AVMXY: 14.14 )
Ranked among companies with meaningful Price/Tangible Book only.
AVMXY' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.47  Med: 2.75 Max: 18.33
Current: 14.14
0.47
18.33
Price/Median PS Value 6.83
AVMXY's Price/Median PS Value is ranked lower than
97% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. AVMXY: 6.83 )
Ranked among companies with meaningful Price/Median PS Value only.
AVMXY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.43  Med: 1.5 Max: 14
Current: 6.83
0.43
14
Earnings Yield (Greenblatt) (%) -13.20
AVMXY's Earnings Yield (Greenblatt) (%) is ranked lower than
75% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. AVMXY: -13.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AVMXY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -14.36  Med: 351.7 Max: 11345.6
Current: -13.2
-14.36
11345.6

More Statistics

Revenue (TTM) (Mil) $0.73
EPS (TTM) $ -0.26
Beta0.11
Short Percentage of Float0.00%
52-Week Range $1.35 - 2.46
Shares Outstanding (Mil)33.65
» More Articles for AVMXY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Presentations at French Society of Plastic, Reconstructive and Aesthetic Surgery Reinforce Benefits... Nov 28 2016
AVITA MEDICAL, LTD. Financials Nov 15 2016
Innovative Regenerative Approach to Healing Diabetic Foot Ulcers Now Being Trialed at Two Additional... Nov 08 2016
Avita Medical's ReCell(R) devices now treating burns in South Africa and Benelux Oct 19 2016
U.S. FDA Approves increased Compassionate Use Patient Cases and Sites for ReCell(R) in... Oct 18 2016
Avita Medical to Present at the 2016 Dawson James Securities Growth Stock Conference in Florida Oct 13 2016
FDA Approves Continued Access to ReCell(R) in US Burns Trial Oct 04 2016
'Spray on skin' maker sets sights on Iran Sep 29 2016
Avita Medical Signs Exclusive Distributor Deal in Iran Sep 28 2016
Avita Medical to Hold ReCell(R) Symposium at Leading European Burns Association Course Sep 22 2016
ISBSI – Avita Medical’s Regenerative Skin Technology significantly reduces burn scars and... Sep 02 2016
Avita Medical's Regenerative Skin Technology Significantly Reduces Burn Scars and Healing Time Sep 01 2016
Avita Medical Announces Financial Results for Fourth Quarter Fiscal 2016 Jul 28 2016
Avita Medical Announces Rights Issue Raises $9 Million Jul 10 2016
Avita Medical Appoints a Leading Health Economics Group Jun 28 2016
Regenerative Medicine Publishes Key Findings From Avita Medical's 2016 Skin Regeneration Symposium Jun 27 2016
Avita wins $US8m contract extension Jun 26 2016
Avita Medical Awarded US$7.96m in BARDA Extension Deal Jun 26 2016
Avita Medical to Present at Global Chinese Financial Forum Jun 22 2016
Avita Medical Appoints a COO and a VP of Sales and Marketing Jun 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)